两家企业跻身“百强” 南京江北新区生物医药产业快速发展

Group 1 - The 2024 list of China's top 100 pharmaceutical companies highlights the concentration and high-quality development of the pharmaceutical industry, with two companies from Nanjing, Xiansheng Pharmaceutical and Jianyou Co., Ltd., making the list [1] - Xiansheng Pharmaceutical has over 74% of its revenue coming from innovative drugs, with 10 innovative drugs launched, including the recently approved Enzeshushu, a targeted drug for platinum-resistant ovarian cancer [1] - Jianyou Co., Ltd. is a leading producer of heparin raw materials in China, successfully entering high-end markets in Europe and the United States, with a global customer base that includes Pfizer, Merck, and Sanofi [1] Group 2 - The "2025 China Drug R&D Strength Rankings" emphasizes "R&D value," with three companies from Nanjing's Jiangbei New District Biopharmaceutical Valley making the list, including Jianyou Co., Ltd. and Yaoshi Technology [2] - The rankings are based on various metrics, including drug approval status, R&D investment, clinical trial performance, and patent scores, reflecting the highest standards in China's CRO/CDMO industry [2] - Yaoshi Technology is recognized as a global leader in drug development, having collaborated with over 80% of the top 20 pharmaceutical companies worldwide [3] Group 3 - The Nanjing Jiangbei New District Biopharmaceutical Valley has gathered over 1,300 biopharmaceutical companies, indicating a robust industry cluster [4]